{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:15:52Z","timestamp":1771665352521,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.gore.2025.102008","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:32:57Z","timestamp":1765931577000},"page":"102008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies"],"prefix":"10.1016","volume":"63","author":[{"given":"Minyoung","family":"Jang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Gysler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawar A.","family":"Latif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily M.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"Robert L.","family":"Giuntoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Simpkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Nasioudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2025.102008_b0005","unstructured":"AACR Project GENIE. (2025, July 16). AACR Project GENIE 18.0\u2014Public Data Guide. American Association for Cancer Research. https:\/\/www.aacr.org\/wp-content\/uploads\/2025\/08\/18.0-data_guide.pdf."},{"issue":"8","key":"10.1016\/j.gore.2025.102008_b0010","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: Powering Precision Medicine through an International Consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.gore.2025.102008_b0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/path.4088","article-title":"Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas","volume":"229","author":"Anglesio","year":"2013","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.gore.2025.102008_b0020","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/IGC.0000000000001138","article-title":"Mutational aberrations detected in mucinous epithelial ovarian cancer of asian women","volume":"28","author":"Chay","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.gore.2025.102008_b0025","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1038\/s41467-019-11862-x","article-title":"The molecular origin and taxonomy of mucinous ovarian carcinoma","volume":"10","author":"Cheasley","year":"2019","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.gore.2025.102008_b0030","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1073\/pnas.0408593102","article-title":"A survey of homozygous deletions in human cancer genomes","volume":"102","author":"Cox","year":"2005","journal-title":"Proceed. National Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.gore.2025.102008_b0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jmoldx.2014.10.006","article-title":"Target-enriched next-generation sequencing reveals differences between primary and secondary ovarian tumors in formalin-fixed, paraffin-embedded tissue","volume":"17","author":"Crobach","year":"2015","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.gore.2025.102008_b0040","doi-asserted-by":"crossref","unstructured":"Dundr, P., B\u00e1rt\u016f, M., Bosse, T., Bui, Q. H., Cibula, D., Drozenov\u00e1, J., Fabian, P., Fadare, O., Hausnerov\u00e1, J., Hojn\u00fd, J., H\u00e1jkov\u00e1, N., Jak\u0161a, R., Laco, J., Lax, S. F., Mat\u011bj, R., M\u00e9hes, G., Mich\u00e1lkov\u00e1, R., \u0160afanda, A., N\u011bmejcov\u00e1, K., \u2026 McCluggage, W. G., 2023. Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 36(1), pp. 100040. doi: 10.1016\/j.modpat.2022.100040.","DOI":"10.1016\/j.modpat.2022.100040"},{"issue":"23","key":"10.1016\/j.gore.2025.102008_b0045","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.gore.2025.102008_b0050","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1158\/1078-0432.CCR-05-1008","article-title":"Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas","volume":"11","author":"Feltmate","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"269","key":"10.1016\/j.gore.2025.102008_b0055","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"issue":"11","key":"10.1016\/j.gore.2025.102008_b0060","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","article-title":"CDK4\/6 inhibition in cancer: beyond cell cycle arrest","volume":"28","author":"Goel","year":"2018","journal-title":"Trends Cell Biol."},{"issue":"3","key":"10.1016\/j.gore.2025.102008_b0065","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ygyno.2019.03.256","article-title":"An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC\/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor","volume":"153","author":"Gore","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2025.102008_b0070","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ygyno.2019.12.015","article-title":"Therapeutic options for mucinous ovarian carcinoma","volume":"156","author":"Gorringe","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2025.102008_b0075","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.gore.2025.102008_b0080","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1158\/1078-0432.CCR-12-1103","article-title":"Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations","volume":"18","author":"Hunter","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gore.2025.102008_b0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2019.04.149","article-title":"Comprehensive genomic profiling of mucinous ovarian carcinoma with comparisons to mucinous colorectal carcinoma","volume":"154","author":"Jones","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2025.102008_b0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","article-title":"MAT2A inhibition blocks the growth of MTAP-Deleted cancer cells by reducing PRMT5-Dependent mRNA splicing and inducing DNA damage","volume":"39","author":"Kalev","year":"2021","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.gore.2025.102008_b0095","doi-asserted-by":"crossref","first-page":"e1864","DOI":"10.1634\/theoncologist.2020-0681","article-title":"Phase II Trial of Palbociclib in patients with Advanced Esophageal or Gastric Cancer","volume":"25","author":"Karasic","year":"2020","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.gore.2025.102008_b0100","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a Small-Molecule Inhibitor of KrasG12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.gore.2025.102008_b0105","doi-asserted-by":"crossref","unstructured":"Kryukov, G.V., Wilson, F.H., Ruth, J.R., Paulk, J., Tsherniak, A., Marlow, S.E., Vazquez, F., Weir, B.A., Fitzgerald, M.E., Tanaka, M., Bielski, C.M., Scott, J.M., Dennis, C., Cowley, G.S., Boehm, J.S., Root, D.E., Golub, T.R., Clish, C.B., Bradner, J.E., \u2026 Garraway, L.A., 2016. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science (New York, N.Y.), 351(6278), pp. 1214\u20131218. doi: 10.1126\/science.aad5214.","DOI":"10.1126\/science.aad5214"},{"issue":"5","key":"10.1016\/j.gore.2025.102008_b0110","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/0008-5472.CAN-20-2275","article-title":"Functional determinants of cell cycle plasticity and sensitivity to CDK4\/6 inhibition","volume":"81","author":"Kumarasamy","year":"2021","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.gore.2025.102008_b0115","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int. J. Gynecolog. Cancer: Official J. Int. Gynecolog. Cancer Soc."},{"key":"10.1016\/j.gore.2025.102008_b0120","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s12885-015-1421-8","article-title":"Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms","volume":"15","author":"Mackenzie","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.gore.2025.102008_b0125","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/1471-2407-9-433","article-title":"HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","volume":"9","author":"McAlpine","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.gore.2025.102008_b0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2022.10.022","article-title":"Profiling the immune landscape in mucinous ovarian carcinoma","volume":"168","author":"Meagher","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2025.102008_b0135","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ygyno.2018.07.013","article-title":"Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials","volume":"150","author":"Meagher","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2025.102008_b0140","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.gore.2025.102008_b0145","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMra1813254","article-title":"Mucinous ovarian carcinoma","volume":"380","author":"Morice","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.gore.2025.102008_b0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2018.05.008","article-title":"Massively parallel sequencing analysis of mucinous ovarian carcinomas: Genomic profiling and differential diagnoses","volume":"150","author":"Mueller","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2025.102008_b0155","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00404-020-05489-3","article-title":"Advanced stage primary mucinous ovarian carcinoma. where do we stand\u00a0?","volume":"301","author":"Nasioudis","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"issue":"2","key":"10.1016\/j.gore.2025.102008_b0160","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ygyno.2019.05.009","article-title":"Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma","volume":"154","author":"Nasioudis","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2025.102008_b0165","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.gore.2025.102008_b0170","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14656566.2023.2201373","article-title":"Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?","volume":"24","author":"Perrone","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.gore.2025.102008_b0175","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.yexmp.2013.08.004","article-title":"TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type","volume":"95","author":"Rechsteiner","year":"2013","journal-title":"Exp. Mol. Pathol."},{"issue":"1","key":"10.1016\/j.gore.2025.102008_b0180","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13073-015-0210-y","article-title":"Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors","volume":"7","author":"Ryland","year":"2015","journal-title":"Genome Med."},{"issue":"25","key":"10.1016\/j.gore.2025.102008_b0185","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.gore.2025.102008_b0190","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ygyno.2016.12.002","article-title":"Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)","volume":"144","author":"Spreafico","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2025.102008_b0195","doi-asserted-by":"crossref","first-page":"13837","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.gore.2025.102008_b0200","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2021.10.072","article-title":"Probability of detecting germline BRCA1\/2 pathogenic variants in histological subtypes of ovarian carcinoma A Meta-Analysis","volume":"164","author":"Witjes","year":"2022","journal-title":"Gynecologic Oncol."},{"issue":"6","key":"10.1016\/j.gore.2025.102008_b0205","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and Safety of Adagrasib plus Cetuximab in patients with KRASG12C-mutated Metastatic Colorectal Cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925003339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925003339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:22:03Z","timestamp":1771662123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578925003339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":41,"alternative-id":["S2352578925003339"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.102008","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.102008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102008"}}